{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/considerations-pediatric-vaccine-trials-developing-countries#webpage",
"url": "https://www.fortrea.com/insights/considerations-pediatric-vaccine-trials-developing-countries",
"name": "Considerations for pediatric vaccine trials in developing countries",
"description": "Fortrea White Paper examines the critical considerations for conducting pediatric vaccine trials in developing countries, where the burden of infectious diseases is highest yet representation in vaccine research has historically been limited. The paper explores the evolving landscape of pediatric vaccine clinical trials across low- and middle-income countries (LMICs), highlighting the importance of community engagement, culturally appropriate communication, health literacy and informed consent in supporting participant recruitment and retention. It addresses operational challenges including cold chain management, site infrastructure, resource limitations, workforce training and clinical trial capacity building, while also examining the complexities of pediatric vaccine safety monitoring in populations affected by varying health and environmental conditions. Additional focus is placed on ethical considerations, comparator selection, participant protection, regulatory variability and long-term strategies for strengthening local research capabilities and healthcare systems. By integrating ethical research practices, sustainable capacity building and region-specific operational planning, the white paper provides a framework for designing effective pediatric vaccine trials that support both scientific rigor and global health equity. "
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Considerations for pediatric vaccine trials in developing countries",
"item": "https://www.fortrea.com/insights/considerations-pediatric-vaccine-trials-developing-countries"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/considerations-pediatric-vaccine-trials-developing-countries#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/considerations-pediatric-vaccine-trials-developing-countries#webpage"
},
"headline": "Pediatric Vaccine Trials in Developing Countries Through Community Engagement, Ethical Research and Capacity Building | Fortrea White Paper",
"description": "Fortrea White Paper examines the critical considerations for conducting pediatric vaccine trials in developing countries, where the burden of infectious diseases is highest yet representation in vaccine research has historically been limited. The paper explores the evolving landscape of pediatric vaccine clinical trials across low- and middle-income countries (LMICs), highlighting the importance of community engagement, culturally appropriate communication, health literacy and informed consent in supporting participant recruitment and retention. It addresses operational challenges including cold chain management, site infrastructure, resource limitations, workforce training and clinical trial capacity building, while also examining the complexities of pediatric vaccine safety monitoring in populations affected by varying health and environmental conditions. Additional focus is placed on ethical considerations, comparator selection, participant protection, regulatory variability and long-term strategies for strengthening local research capabilities and healthcare systems. By integrating ethical research practices, sustainable capacity building and region-specific operational planning, the white paper provides a framework for designing effective pediatric vaccine trials that support both scientific rigor and global health equity. ",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/considerations-for-pediatric-vaccine-trials-developing-countries_1.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-10",
"dateModified": "2025-02-10",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/considerations-for-pediatric-vaccine-trials-developing-countries.pdf",
"encodingFormat": "application/pdf"
}
}
]
}